ImmuPharma plc (LON:IMM – Get Free Report) shot up 25.6% during trading on Friday . The company traded as high as GBX 5.70 ($0.07) and last traded at GBX 4.90 ($0.06). 16,251,525 shares changed hands during mid-day trading, a decline of 25% from the average session volume of 21,707,736 shares. The stock had previously closed at GBX 3.90 ($0.05).
ImmuPharma Stock Up 23.8 %
The company has a fifty day moving average price of GBX 2.39 and a two-hundred day moving average price of GBX 1.93. The firm has a market capitalization of £20.11 million, a price-to-earnings ratio of -483.00 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- How to Use High Beta Stocks to Maximize Your Investing Profits
- IBM’s AI Bet Pays Off—What’s Next for Investors?
- How to Choose Top Rated Stocks
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
